Efficacy of transcatheter arterial chemoembolization (TACE) with miriplatin for multiple hepatocellular carcinoma refractory or inappropriate to conventional TACE
Phase 2
Recruiting
- Conditions
- Multiple hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000010291
- Lead Sponsor
- Department of Surgery, Graduate School of Medicine Kyoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with another active cancer 2) Patients with extrahepatic metastasis 3) Patients with prior surgical reconstruction of the biliary tract or prior endoscopic treatment of ampulla of vater 4) Patients with clinically significant refractory ascites or pleural effusion 5) Patients with hepatic encephalopathy 6) Patients with severe co-morbidity such as cardiac failure and renal failure 7) Patients with a medical history of severe hypersensitivity 8) Patients who are pregnant, lactating or are suspected to be pregnant. 9) Patients who are concluded to be inappropriate to participate in this study by their physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate (based on RECICL or mRECIST)
- Secondary Outcome Measures
Name Time Method Progression free survival Disease control rate Safety 1y survival rate